Cyclin-Dependent Kinase 4
Transforming Glaucoma Care With Rho Kinase Inhibitors
This activity is supported by an educational grant from Alcon Vision, LLC.
VIDEO: Metastatic breast cancer converting to a 'chronic disease' with new treatments
In this video, Aruna Padmanabhan, MD, discusses the effectiveness of cyclin-dependent kinase inhibitors in the treatment of metastatic hormone-positive breast cancer.
Imlunestrant alone, with abemaciclib delays progression of advanced breast cancer
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.
Highlights from SABCS 2022
In this episode of Meeting Mic, we bring you the highlights and insights from the SABCS 2022, as well as Healio’s top headlines from the meeting.
Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer
SAN ANTONIO — Longer duration of cyclin-dependent kinase 4/6 inhibitor therapy in the metastatic setting appeared associated with extended PFS among elacestrant-treated patients with advanced breast cancer, according to study results.
CDK 4/6 inhibitors effective across age groups in breast cancer subset
Combinations of cyclin-dependent kinase 4/6 inhibitors and aromatase inhibitors appeared effective among older and younger women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with aromatase inhibitors alone, according to results of an FDA pooled analysis published in Journal of Clinical Oncology.